Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

In a study of 2286 patients with type 2 diabetes, reductions in HbA1c with empagliflozin were significantly lower in those with decreased kidney function.

• Reductions in HbA1c with empagliflozin diminished as baseline estimated glomerular filtration rate (eGFR) decreased.
• Systolic blood pressure reductions with empagliflozin were maintained even in patients with lower eGFR levels.
• Placebo-corrected changes in systolic blood pressure at week 24 varied with eGFR, ranging from -3.2 mmHg in patients with eGFR of 90 or more to -6.6 mmHg in those with eGFR under 30 ml/min/1.73m.
• Similar trends for diastolic blood pressure were also observed.
• Weight loss with empagliflozin was generally less pronounced in patients with lower eGFR.
• Results were consistent with findings from a smaller 12-week ambulatory blood pressure monitoring trial involving 823 patients.

AI simplified